𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia

✍ Scribed by Kristine Doney; Rainer Storb; Frederick R. Appelbaum; C. Dean Buckner; Jean Sanders; Jack Singer; John A. Hansen

Book ID
114713457
Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
282 KB
Volume
85
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of severe aplastic anemia with
Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin
✍ Zonghong Shao; Yulin Chu; Yizhi Zhang; Guibin Chen; Yizhou Zheng πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 44 KB πŸ‘ 2 views

To evaluate the therapeutic potential of hematopoietic growth factors (HGFs) during immunosuppressive treatment (IST) of severe aplastic anemia (SAA), 38 patients with newly diagnosed SAA received IST alone (group I), or IST plus recombinant human erythropoietin and granulocyte-macrophage colony-sti

Combination Therapy With Recombinant Hum
Combination Therapy With Recombinant Human Granulocyte Colony-Stimulating Factor and Erythropoietin in Aplastic Anemia
✍ Dr. Masahiro Imamura; Masanobu Kobayashi; Sumiko Kobayashi; Kohki Yoshida; Chika πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 430 KB πŸ‘ 1 views

## Abstract Recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) and erythropoietin (rhEPO) were used to treat patients with aplastic anemia (AA). In terms of effects on erythrocyte recovery, the combined use of rhG‐CSF and rhEPO showed a favorable response in 6 of 14 (42.9%) patients

Recombinant Interleukin-1 Followed by im
Recombinant Interleukin-1 Followed by immunosuppressive therapy for aplastic anemia
✍ Kristine Doney; Rainer Store; Kathy Lilleby; Frederick R. Appeleaum πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 250 KB πŸ‘ 1 views

A survay of 214 non-hemophilic patients with inhibitors to 2. Green D: Suppression of an antibody to factor VlII by a combination of factor 3. Ting HC, Wang F, Por P, Nurulhuda A: Idiopathic Inhibitor of factor VIlI and its 4. Green D: Immunosuppression of factor VIII inhibitors in nonhemophilic pat